Hagerty, Inc. (HGTY) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +44.44%. A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.13, delivering a surprise of +18.18%.Over the last four quarters, the company ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Sealed Air (SEE) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +27.94%. A quarter ago, it was expected that this packaging company would post earnings of $0.72 per share when it actually produced earnings of $0.89, delivering a surprise of +23.61%.Over the last four quarters, the co ...

PJT Partners (PJT) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $0.93 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +49.19%. A quarter ago, it was expected that this investment bank would post earnings of $1.36 per share when it actually produced earnings of $1.54, delivering a surprise of +13.24%.Over the last four quarters, the co ...

Imagine waking up tomorrow to find that every dollar of America’s $18 trillion-plus in credit card debt had been wiped clean. No interest, no minimum payments, no late fees, all of it gone. Find Out: I Asked ChatGPT What Would Happen If Billionaires Paid Taxes at the Same Rate as the Middle Class Read Next: 9 Low-Effort Ways To Make Passive Income (You Can Start This Week) While that might sound like a dream come true for millions of consumers, what would it actually mean for the average American, for the ...

NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemiaMENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical Products ...

Accessibility StatementSkip Navigation INDIANAPOLIS, Nov. 4, 2025 /PRNewswire/ -- Carrier is proud to announce a major milestone in its commitment to advancing the future of sustainable HVAC solutions. Multiple Carrier 'My Learning Center Heat Pump Training' programs have been officially recognized by the U.S. Department of Energy (DOE) as an Energy Skilledâ"¢ training provider in the category of Heat Pump Installation. This designation highlights Carrier's efforts to equip HVAC technicians with the skill ...

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD. Details of the poster presentation are as follows: Title: A Phase II Trial of Combination Locoregional Chemoimmunot ...

Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces it will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer (SITC) conference being held November 5-9, 2025 in National Harbor, Md. The poster ...

CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that preclinical data from CR-001, its PD-1 x VEGF bispeci ...